-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma - What Clinicians Want to Know

Sponsor: educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group and Regeneron Pharmaceuticals Inc.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Lymphomas, Clinical Research, Education, Diseases, Treatment Considerations, Lymphoid Malignancies, Adverse Events
Friday, December 6, 2024: 11:00 AM-2:00 PM
Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)
Chair:
Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center
Disclosures:
Abramson: AbbVie Inc: Consultancy; Cellectis: Research Funding; Incyte Corporation: Consultancy; Genmab US Inc: Consultancy; Genentech, a member of the Roche Group: Consultancy; Century Therapeutics: Consultancy; Seagen Inc.: Research Funding; Merck: Research Funding; Mustang Bio: Research Funding; Caribou Biosciences Inc: Consultancy; BeiGene Ltd: Consultancy; Interius BioTh: Consultancy; AstraZeneca Pharmaceuticals LP: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; Epizyme Inc: Consultancy; Foresight Diagnostics: Consultancy.
Speakers:
Jennifer L. Crombie, MD, Dana-Farber Cancer Institute , Martin Hutchings, MD, PhD, Copenhagen University Hospital - Rigshospitalet , Matthew Lunning, DO, University of Nebraska Medical Center and Tycel J. J. Phillips, MD, City of Hope
Disclosures:
Crombie: Merck: Research Funding; Genentech/Roche: Research Funding; Bayer: Research Funding; Abbvie: Research Funding; Genentech: Consultancy; Genmab/Abbvie: Consultancy; Seagen: Consultancy; Regeneron Pharmaceuticals, Inc.: Consultancy; ADCT: Consultancy. Hutchings: BMS/Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genmab: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Research Funding; Incyte: Research Funding; Janssen/J&J: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Research Funding. Lunning: Daiichi Sankyo, Fate Therapeutics, Genentech, Genmab, Ipsen, Janssen: Consultancy, Honoraria; Kite, Lilly, Incyte, Recordati, Regeneron, SeaGen, ViTToria: Consultancy, Honoraria; Abbvie, Acrotech, ADC Therapeutics, Astrazeneca, Britsol-Myers Squibb, Caribou, CRISPR,: Consultancy, Honoraria; AbbVie, Bristol Myers Squibb, Fate Therapeutics, Sana Therapeutics, Kite: Consultancy, Research Funding. Phillips: AbbVie Inc, Genentech, a member of the Roche Grou: Research Funding; Genentech, a member of the Roche Group.: Membership on an entity's Board of Directors or advisory committees; AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol Myers Squibb, Epizyme Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Pharmacy: Consultancy; AbbVie Inc, Genentech, a member of the Roche Group, Genmab US Inc, Merc: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics, Lymphoma & Myeloma Connect: Honoraria; AbbVie, Pharmacyclics/Janssen, Bayer: Other: Scholar in Clinical Research of The Leukemia & Lymphoma Society, Research Funding.

This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the utilization of CAR T-cell therapy and bispecific antibodies in the care of patients with non-Hodgkin lymphoma. Five clinical investigators will serve as faculty for the program, one of whom will moderate. Prior to the symposium. Research To Practice (RTP) recruit 4 general medical oncologists/hematologists to consult on the project. The clinicians will participate in a working group session during which they will voice challenging questions and cases from their practices and help shape the content for the symposium. The entire session will be recorded and video segments will be adapted for presentation during the event. The agenda for the symposium will be divided into 5 modules. To begin each module, the moderator will play select video excerpts from the working group for the audience and the faculty. Moderated panel discussion will ensue to provide expert perspectives and answers to the questions introduced. A faculty member-led review of related research findings will complete each module. To make the event even more engaging, attendees will use iPads to submit their own questions and cases. Virtual attendees will have the same capability via the webcast platform.